Lundbeck and Otsuka will initiate a third phase III trial to evaluate the use of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type
Valby, Denmark and Tokyo, Japan, 1 November 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce that the two companies will initiate a third clinical phase III study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type. The trial is expected to commence during the first half of 2018. The decision to initiate a third trial follows discussions with the U.S. Food and Drug Administration (FDA) in October regarding the two, completed phase III clinical trials for the agitation indication that were completed by